PPMP as a Ceramide Catabolism Inhibitor for Chemotherapy

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R41CA102842-01
Agency Tracking Number: CA102842
Amount: $249,947.00
Phase: Phase I
Program: STTR
Awards Year: 2003
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
Avanti Polar Lipids, Inc.
700 INDUSTRIAL PARK DR, 700 INDUSTRIAL PARK DR, Alabaster, AL, 35007
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 BARRY MAURER
 (323) 669-5663
 BMAURER@CHLA.USC.EDU
Business Contact
Phone: (205) 663-2494
Research Institution
 CHILDREN'S HOSPITAL LOS ANGELES
 4650 SUNSET BLVD
LOS ANGELES, CA, 90027
 Domestic nonprofit research organization
Abstract
DESCRIPTION (provided by applicant): Our goal is to develop 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) as a clinical inhibitor of ceremide catabolism, in order to enhance the anti-cancer activity of the cytotoxic retinoid, fenretinide (4-HPR). We have reported that 4-HPR increased ceramide in numerous pediatric and adult solid cancer and leukemia cell lines in vitro. We have also reported that PPMP, an inhibitor of glucosylceramide synthase and l-O-acylceramide synthase, further increased ceramide and synergized 4-HPR cytotoxicity. We hypothesize that intravenous or oral formulations of PPMP can achieve plasma and tissue levels that inhibit ceramide catabolism in vitro. We hypothesize that PPMP will enhance the anti-cancer effect of 4-HPR with tolerable systemic toxicity in vivo. We will: AIM 1. Identify the stereoisomer of PPMP that most effectively inhibits ceramide catabolism and increases 4-HPR cytotoxicity. AIM 2. Develop a cGMP process, and produce PPMP for pre-IND studies. AIM 3. Formulate PPMP for intravenous and/or oral delivery. AIM 4. Perform small animal pharmacokinetic and toxicology studies to support a Phase II STTR application to support IND-directed toxicology studies and cGMP PPMP manufacture for Phase I clinical trial. 4-HPR+PPMP represents a novel, p53-independent chemotherapy that is based upon the generation and manipulation of ceramide in vivo.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government